A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 500 participants.

Also called NCT05144984

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 500 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT05144984
  • EudraCT 2020-004863-14
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Bulgaria, Denmark, Greece, Hungary, Japan, Poland, Russia, Serbia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05144984. Randomized; quadruple masking; primary purpose treatment. Start 2021-11-29 (actual); primary completion 2023-02-13 (actual). Results posted on 2026-04-09.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
NNC0480-0389
Intervention (Drug)
Semaglutide
Intervention (Drug)
Placebo (NNC080-0389)
Intervention (Drug)
Placebo (semaglutide)
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct05144984
Content hash
47335105e87fe537bc7ef8585d1ba47aae8ecbcceadbb3d0c11dd5aacd471f81